PD 407824

PD 407824 is a potent, cell-permeable small molecule inhibitor of Checkpoint kinase 1 (CHK1) and Checkpoint kinase 2 (CHK2). It acts as a chemosensitizer by abrogating the G2/M cell cycle checkpoint, which is normally activated in response to DNA damage. By preventing this arrest, PD 407824 forces cells with damaged DNA to enter mitosis prematurely, leading to cell death via apoptosis or mitotic catastrophe. This mechanism is particularly effective in enhancing the cytotoxicity of DNA-damaging agents like cisplatin and gemcitabine. Originally developed by Parke-Davis (now Pfizer), PD 407824 is widely utilized in preclinical oncology research to explore the therapeutic potential of targeting the DNA damage response (DDR) pathway, specifically in cancers such as ovarian and pancreatic carcinoma.

Other names

9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione